LCM
UTHR icon

Legato Capital Management’s United Therapeutics UTHR Stock Holding History

Legato Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,864
Closed -$1.11M – 851
2026
Q1 		$1.11M Sell
1,864
-4,658
-71% -$2.32M 0.1% 257
2025
Q4 		$3.18M Hold
6,522
– – 0.27% 79
2025
Q3 		$2.73M Buy
6,522
+1,618
+33% +$544K 0.3% 86
2025
Q2 		$1.41M Hold
4,904
– – 0.17% 187
2025
Q1 		$1.51M Buy
+4,904
New +$1.68M 0.2% 156

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Legato Capital Management's UTHR Position: Q2 2026 in Review

Legato Capital Management sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 1,864 shares — an estimated $1.11M sold.

Legato Capital Management first reported a position in UTHR in Q1 2025 and held it in 5 quarters. The position peaked at $3.18M in Q4 2025. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Legato Capital Management reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Legato Capital Management sold 1,864 United Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Legato Capital Management first reported a position in United Therapeutics in Q1 2025 and held it in 5 quarters.
  • Legato Capital Management's United Therapeutics position peaked at $3.18M in Q4 2025.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.